Trastuzumab Completed Phase 2 Trials for Metastatic Breast Cancer (MBC) Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT01401959Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT00134680Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
NCT00303108Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
NCT00401427HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
NCT00490646A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
NCT01423695Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer